Article
VAV3 mediates resistance to breast cancer endocrine therapy.
Breast cancer research : BCR - 28 May 2014
Aguilar Helena, Urruticoechea Ander, Halonen Pasi, Kiyotani Kazuma, Mushiroda Taisei, Barril Xavier, Serra-Musach Jordi, Islam Abul, Caizzi Livia, Di Croce Luciano, Nevedomskaya Ekaterina, Zwart Wilbert, Bostner Josefine, Karlsson Elin, Pérez Tenorio Gizeh, Fornander Tommy, Sgroi Dennis C, Garcia-Mata Rafael, Jansen Maurice P H M, García Nadia, Bonifaci Núria, Climent Fina, Soler María Teresa, Rodríguez-Vida Alejo, Gil Miguel, Brunet Joan, Martrat Griselda, Gómez-Baldó Laia, Extremera Ana I, Figueras Agnes, Balart Josep, Clarke Robert, Burnstein Kerry L, Carlson Kathryn E, Katzenellenbogen John A, Vizoso Miguel, Esteller Manel, Villanueva Alberto, Rodríguez-Peña Ana B, Bustelo Xosé R, Nakamura Yusuke, Zembutsu Hitoshi, Stål Olle, Beijersbergen Roderick L, Pujana Miguel Angel
Abstract excerpt
INTRODUCTION: Endocrine therapies targeting cell proliferation and survival mediated by estrogen receptor α (ERα) are among the most effective systemic treatments for ERα-positive breast cancer. However, most tumors initially responsive to these therapies acquire resistance through mechanisms that involve ERα transcriptional regulatory plasticity. Herein we identify VAV3 as a critical component in this process....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.